evaluation of the efficacy of eicosapentaenoic acid in patients with chronic migraine headache

Evaluation of the efficacy of eicosapentaenoic acid in patients with chronic migraine headache; a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170608034390N9

Enrollment

Registered

2022-05-11

Start date

2022-06-22

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic migraine. Migraine

Interventions

Intervention 1: The intervention group will receive 2000 mg of EPA daily in the form of add on treatment, products are softgels containing 1000 mg of EPA-ethyl ester (EPA-EE) made by Yas Kavir Pharmac

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with chronic migraine based on the ICHD-3 criteria Ages between 18 and 50 Provide written consent

Exclusion criteria

Exclusion criteria: Contraindications to EPA such as allergies Patients with a history of bleeding disorders Patients with increased risk of bleeding Pregnant patients Lactating patients Patients treated with antiplatelet or anticoagulant drugs

Design outcomes

Primary

Measure	Time frame
Headache impact test 6 (HIT-6). Timepoint: The frequency, severity and duration of headaches are measured monthly for two months. Method of measurement: Headache impact test 6 (HIT-6).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Esmaily

Shahid Beheshti University of Medical Sciences

Esmaily_hadi@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026